<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430887</article-id><article-id pub-id-type="pmcid-ver">PMC12430887.1</article-id><article-id pub-id-type="pmcaid">12430887</article-id><article-id pub-id-type="pmcaiid">12430887</article-id><article-id pub-id-type="pmid">40503765</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002738</article-id><article-id pub-id-type="publisher-id">IJS-D-25-02679</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Letter to Editor: &#8220;The lncRNAs PART1 and ADAMTS9-AS2 act in an antithetic manner on AR signaling and induction of cellular senescence in prostate cancer cells&#8221;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="Y">Yongzheng</given-names></name><degrees>MSc</degrees><email>146220318@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xu</surname><given-names initials="Y">Yun</given-names></name><degrees>MSc</degrees><email>744048121@qq.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2300-8465</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="G">Guangzhen</given-names></name><degrees>MD</degrees><email>wuguang0613@hotmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, China</aff><aff id="aff2"><label>b</label>Department of Nursing, the First Affiliated Hospital of Dalian Medical University, Dalian, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Nursing, The First Affiliated Hospital of Dalian Medical University, Dalian 116011 Liaoning, China. Tel.: +86 8098872685. E-mail: <email>744048121@qq.com</email> (Y. Xu), Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011 Liaoning, China. Tel.: +86 1809887601. E-mail: <email>wuguang0613@hotmail.com</email> (G. Wu).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6563</fpage><lpage>6564</lpage><history><date date-type="received"><day>31</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0</ext-link> (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6563.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6563.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<italic toggle="yes">Dear Editor,</italic>
</p><p>We are writing to commend the recent article by Mohammad Taheri <italic toggle="yes">et al</italic>, titled <bold><italic toggle="yes">&#8220;The lncRNAs PART1 and ADAMTS9-AS2 act in an antithetic manner on AR signaling and induction of cellular senescence in prostate cancer cells</italic></bold><sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup><bold><italic toggle="yes">,&#8221;</italic></bold>published in the <bold><italic toggle="yes">International Journal of Surgery</italic></bold>. Androgen receptor (AR) interact with multiple signaling pathways to promote the occurrence and progression of prostate cancer<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. Therefore, clarifying the AR signaling mechanism is crucial for the treatment of prostate cancer. This study has made significant contributions to the field of prostate cancer research, enabling people to have a deeper understanding of the role of long non-coding RNAs (lncRNAs) in tumorigenesis. We hereby declare that this manuscript was translated and linguistic checked using artificial intelligence to ensure compliance with journal requirements. The TITAN Guideline checklist was submitted according to the requirements of the literature <bold><italic toggle="yes">&#8220;Transparency In the reporting of Artificial Intelligence-The TITAN guideline&#8221;</italic></bold><sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>.</p><p>This study showed that PART1 acts as a co-repressor of AR signaling and ADAMTS9-AS2 as a co-activator. Specifically, in prostate cancer cells, supraphysiological androgen levels (SAL) up-regulate ADAMTS9-AS2 and down-regulate PART1. The authors showed that ADAMTS9-AS2 enhances AR activity and PART1 inhibits it. The opposite regulation of AR signaling by these two lncRNAs also affected cell senescence, with ADAMTS9-AS2 promoting Sal-induced senescence and PART1 inhibiting Sal-induced senescence in prostate cancer cells. This literature significantly enhances our understanding of the pathogenesis of prostate cancer and clarifies innovative treatment approaches. This work reflects the journal&#8217;s commitment to publishing transformative surgical science characterized by outstanding scientific precision and originality.</p><p>This study identified potential diagnostic markers and therapeutic targets by clarifying the effects of these lncRNAs on AR signaling, a key driver of prostate cancer development, which holds significant clinical significance. These findings may be especially beneficial for the treatment of advanced or castration-resistant prostate cancer. Additionally, the study provides a reliable platform for assessing tumor behavior and the effectiveness of specific treatments.</p><p>However, this groundbreaking research also raises further questions worthy of attention:
<list list-type="bullet"><list-item><p>How do the expression levels of PART1 and ADAMTS9-AS2 fluctuate as prostate cancer progresses from localized to metastatic stages? Clarifying this issue can reveal the optimal period for the intervention treatment of prostate cancer with lncRNAs.</p></list-item><list-item><p>Could the author please elaborate on the potential advantages of combining lncRNA-targeted therapy with current androgen receptor pathway inhibitors (ARPIs)? Specifically, how might such combinations enhance the induction of cellular senescence and assist in overcoming resistance mechanisms in prostate cancer cells?</p></list-item><list-item><p>Does targeting the ADAMTS9-AS2/hsa-miR-7-5p/CAV1 axis enhance SAL-induced drug-resistant tumor senescence? This study revealed this regulatory axis through bioinformatics analysis. Specifically, can the treatment targeting this axis exert a synergistic effect with bipolar androgen therapy and overcome the drug resistance mechanism by increasing the cellular senescence pathway?</p></list-item></list></p><p>Taheri <italic toggle="yes">et al</italic> clarified a key axis of AR signal transduction, paving the way for lncRNAs-targeted therapy of castration-resistant prostate cancer. We appreciate the author&#8217;s academic contributions and believe that these questions will support the further refinement of this promising research trajectory.</p></body><back><fn-group><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 12 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>This study did not involve patients or procedures requiring ethical approval. All data utilized were derived from publicly available sources/literature reviews and did not pertain to individual privacy. Thus, ethical approval was not applicable.</p></sec><sec><title>Consent</title><p>As this study did not involve patients or volunteers, informed consent was not required. No personal details or images of individuals were utilized in the research.</p></sec><sec><title>Sources of funding</title><p>This study was funded by the Dalian Life and Health Field Guidance Plan (2024ZDJH01PT068) and the 2025 Liaoning Provincial Natural Science Foundation.</p></sec><sec><title>Author contributions</title><p>Y.H. drafted the manuscript. Y.X. and G.W. provided critical revisions, and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors have no conflicts to report.</p></sec><sec><title>Guarantor</title><p>Guangzhen Wu.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>This study did not involve human subjects and was based on retrospective data analysis/literature review. Hence, research registration was not applicable.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The data that support the findings of this study are all included in this article.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taheri</surname><given-names>M</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>K</given-names></name><name name-style="western"><surname>Baniahmad</surname><given-names>A</given-names></name></person-group>. <article-title>The lncRNAs PART1 and ADAMTS9-AS2 act in an antithetic manner on AR signaling and induction of cellular senescence in prostate cancer cells</article-title>. <source>Int J Surg</source><year>2025</year>;<volume>111</volume>:<fpage>3646</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">40143747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000002334</pub-id><pub-id pub-id-type="pmcid">PMC12165499</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintero</surname><given-names>JC</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>NF</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Dorantes</surname><given-names>M</given-names></name><name name-style="western"><surname>Camacho-Arroyo</surname><given-names>I</given-names></name></person-group>. <article-title>Cancer stem cells and androgen receptor signaling: partners in disease progression</article-title>. <source>Int J Mol Sci</source><year>2023</year>;<volume>24</volume>:<fpage>15085</fpage>.<pub-id pub-id-type="pmid">37894767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242015085</pub-id><pub-id pub-id-type="pmcid">PMC10606328</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial intelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>